Literature DB >> 33930529

Redox-sensitive Nrf2 and MAPK signaling pathways contribute to trichloroethene-mediated autoimmune disease progression.

Nivedita Banerjee1, Hui Wang1, Gangduo Wang1, Paul J Boor1, M Firoze Khan2.   

Abstract

Trichloroethene (TCE) exposure is associated with the induction of autoimmune diseases (ADs). Although oxidative stress plays a major role in TCE-mediated autoimmunity, the underlying molecular mechanisms still need to be delineated. Dysregulation of redox-sensitive nuclear factor (erythroid-derived 2)-like2 (Nrf2), resulting in uncontrolled antioxidant and cytoprotective genes, and pro-inflammatory MAPK signaling pathways could be critical in TCE-mediated disease progression. This study was, therefore, focused on establishing status and contribution of Nrf2 and MAPK signaling in TCE-mediated inflammatory and autoimmune responses, especially during disease progression. To achieve these objectives, time-response studies were conducted by treating female MRL+/+ mice with TCE (0.5 mg/mL, a dose relevant to human exposure) for 24, 36 and 52 wks. TCE exposure led to reduction in Nrf2 expression, but increased phos-NF-κB (p65) and iNOS along with increased phosphorylation of MAPKs (p38, ERK and JNK) and downstream pro-inflammatory cytokines IL-12, TNF-α and RANTES in the livers in a time-dependent manner. These changes were also associated with time-dependent increases in liver protein carbonyls and induction of serum anti-dsDNA antibodies (marker of systemic lupus erythematosus disease), further supporting the role of oxidative stress and Nrf2/MAPK signaling in TCE-mediated autoimmune response progression. The mechanistic role of MAPK in TCE-mediated autoimmunity was further established by treating MRL+/+ mice with sulforaphane (SFN; 8 mg/kg, i.p., every other day) along with TCE (10 mmol/kg, i.p., every 4th day) for 6 wks using an established protocol, and by in vitro treatment of T cells with dichloroacetyl chloride (a TCE metabolite) with/without p38 MAPK inhibitor. SFN treatment attenuated the TCE-mediated phosphorylation of p38 MAPK. More importantly, treatment with SFN or p38 inhibitor led to suppression of downstream pro-inflammatory cytokines IL-12 and TNF-α. These findings thus support the contribution of Nrf2 and MAPK signaling pathways and help in delineating novel potential therapeutic targets against TCE-mediated autoimmunity. Published by Elsevier B.V.

Entities:  

Keywords:  Autoimmunity; MAPK; Nrf2; Sulforaphane; Trichloroethene

Mesh:

Substances:

Year:  2021        PMID: 33930529      PMCID: PMC8230612          DOI: 10.1016/j.tox.2021.152804

Source DB:  PubMed          Journal:  Toxicology        ISSN: 0300-483X            Impact factor:   4.571


  73 in total

1.  Depletion of Nrf2 enhances inflammation induced by oxyhemoglobin in cultured mice astrocytes.

Authors:  Hao Pan; Handong Wang; Lin Zhu; Lei Mao; Liang Qiao; Xingfen Su
Journal:  Neurochem Res       Date:  2011-08-11       Impact factor: 3.996

Review 2.  Nrf2:INrf2 (Keap1) signaling in oxidative stress.

Authors:  James W Kaspar; Suryakant K Niture; Anil K Jaiswal
Journal:  Free Radic Biol Med       Date:  2009-08-07       Impact factor: 7.376

Review 3.  From T to B and back again: positive feedback in systemic autoimmune disease.

Authors:  M J Shlomchik; J E Craft; M J Mamula
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 4.  New insights into the immunopathogenesis of systemic lupus erythematosus.

Authors:  George C Tsokos; Mindy S Lo; Patricia Costa Reis; Kathleen E Sullivan
Journal:  Nat Rev Rheumatol       Date:  2016-11-22       Impact factor: 20.543

5.  Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE.

Authors:  David S Pisetsky; Diane M Spencer; Peter E Lipsky; Brad H Rovin
Journal:  Ann Rheum Dis       Date:  2018-02-09       Impact factor: 19.103

6.  Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity.

Authors:  A Ippolito; D J Wallace; D Gladman; P R Fortin; M Urowitz; V Werth; M Costner; C Gordon; G S Alarcón; R Ramsey-Goldman; P Maddison; A Clarke; S Bernatsky; S Manzi; S-C Bae; J T Merrill; E Ginzler; J G Hanly; O Nived; G Sturfelt; J Sanchez-Guerrero; I Bruce; C Aranow; D Isenberg; A Zoma; L S Magder; J Buyon; K Kalunian; M A Dooley; K Steinsson; R F van Vollenhoven; T Stoll; M Weisman; M Petri
Journal:  Lupus       Date:  2011-03       Impact factor: 2.911

7.  Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-κB Pathways.

Authors:  Minhee Jang; Ik-Hyun Cho
Journal:  Mol Neurobiol       Date:  2015-06-23       Impact factor: 5.590

Review 8.  Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression.

Authors:  Jong Hun Lee; Tin Oo Khor; Limin Shu; Zheng-Yuan Su; Francisco Fuentes; Ah-Ng Tony Kong
Journal:  Pharmacol Ther       Date:  2012-10-03       Impact factor: 12.310

9.  Inhibition and genetic deficiency of p38 MAPK up-regulates heme oxygenase-1 gene expression via Nrf2.

Authors:  Srivatsava Naidu; Vijith Vijayan; Sentot Santoso; Thomas Kietzmann; Stephan Immenschuh
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

10.  Nitrosative stress and nitrated proteins in trichloroethene-mediated autoimmunity.

Authors:  Gangduo Wang; Jianling Wang; Xuemei Luo; G A Shakeel Ansari; M Firoze Khan
Journal:  PLoS One       Date:  2014-06-03       Impact factor: 3.240

View more
  4 in total

1.  Differential Expression of miRNAs in Trichloroethene-Mediated Inflammatory/Autoimmune Response and Its Modulation by Sulforaphane: Delineating the Role of miRNA-21 and miRNA-690.

Authors:  Nivedita Banerjee; Hui Wang; Gangduo Wang; Paul J Boor; M Firoze Khan
Journal:  Front Immunol       Date:  2022-03-29       Impact factor: 7.561

2.  Gene Differential Expression and Interaction Networks Illustrate the Biomarkers and Molecular Mechanisms of Atherosclerotic Cerebral Infarction.

Authors:  Benzhuo Zhang; Wei Huang; Mingquan Yi; Chunxu Xing
Journal:  J Healthc Eng       Date:  2022-01-12       Impact factor: 2.682

Review 3.  The Potential of Nrf2 Activation as a Therapeutic Target in Systemic Lupus Erythematosus.

Authors:  Michelle T Barati; Dawn J Caster
Journal:  Metabolites       Date:  2022-02-06

4.  Selumetinib - a potential small molecule inhibitor for osteoarthritis treatment.

Authors:  Xiaohang Zheng; Jianxin Qiu; Wenjun Pan; Yuhang Gong; Weikang Zhang; Ting Jiang; Lihua Chen; Weifu Chen; Zhenghua Hong
Journal:  Front Pharmacol       Date:  2022-09-27       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.